Literature DB >> 25976983

Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy.

Fenghua Zhang1,2, Erich M Sturgis1,3, Yan Sun1,4, Yang Zhang1,5, Qingyi Wei6, Caiyun Zhang1,7, Hongliang Zheng1,7, Guojun Li1,3.   

Abstract

Single nucleotide polymorphisms (SNPs) in the promoter region of FAS and FASLG may alter their transcriptional activity. Thus, we determined the associations between four FAS and FASLG promoter variants (FAS1377G>A, rs2234767; 670A>G, rs1800682; FASLG844T>C, rs763110 and 124A>G, rs5030772) and the risk of recurrence of squamous cell carcinoma of the oropharynx (SCCOP). We evaluated the associations between FAS and FASLG genetic variants and the risk of recurrence in a cohort of 1,008 patients. The log-rank test and multivariate Cox models were used to evaluate the associations. Compared with patients with common homozygous genotypes of FAS670 and FASLG844 polymorphisms, patients with variant genotypes had lower disease-free survival rates (log-rank p < 0.0001 and p < 0.0001, respectively) and an approximately threefold higher risk of SCCOP recurrence (HR, 3.2;95% CI, 2.2-4.6; and HR, 3.1; 95% CI, 2.2-4.4, respectively) after multivariate adjustment. Furthermore, among patients with HPV16-positive tumors, those with variant genotypes of these two polymorphisms had lower disease-free survival rates (log-rank, p < 0.0001 and p < 0.0001, respectively) and a higher recurrence risk than did patients with common homozygous genotypes (HR, 12.9; 95% CI, 3.8-43.6; and HR, 8.1; 95% CI, 3.6-18.6, respectively), whereas no significant associations were found for FAS1377 and FASLG124 polymorphisms. Our findings suggest that FAS670 and FASLG844 polymorphisms modulate the risk of recurrence of SCCOP, particularly in patients with HPV16-positive tumors. Larger studies are needed to validate these results.
© 2015 UICC.

Entities:  

Keywords:  FAS and FASLG; apoptosis; biomarkers; genetic variants; head and neck cancer; human papillomavirus; oropharyngeal cancer; recurrence

Mesh:

Substances:

Year:  2015        PMID: 25976983      PMCID: PMC4575831          DOI: 10.1002/ijc.29604

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

1.  Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.

Authors:  Peter Krippl; Uwe Langsenlehner; Wilfried Renner; Herwig Köppel; Hellmut Samonigg
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

2.  Association of TGF-beta1 genetic variants with HPV16-positive oropharyngeal cancer.

Authors:  Xiaoxiang Guan; Erich M Sturgis; Dapeng Lei; Zhensheng Liu; Kristina R Dahlstrom; Qingyi Wei; Guojun Li
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

3.  Fas ligand-induced apoptosis as a mechanism of immune privilege.

Authors:  T S Griffith; T Brunner; S M Fletcher; D R Green; T A Ferguson
Journal:  Science       Date:  1995-11-17       Impact factor: 47.728

4.  Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.

Authors:  Hung-Cheng Lai; Wei-Yu Lin; Ya-Wen Lin; Cheng-Chang Chang; Mu-Hsien Yu; Chia-Chi Chen; Tang-Yuan Chu
Journal:  Gynecol Oncol       Date:  2005-10       Impact factor: 5.482

5.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer.

Authors:  X Zhang; X Miao; T Sun; W Tan; S Qu; P Xiong; Y Zhou; D Lin
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

6.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

7.  Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen.

Authors:  A Oehm; I Behrmann; W Falk; M Pawlita; G Maier; C Klas; M Li-Weber; S Richards; J Dhein; B C Trauth
Journal:  J Biol Chem       Date:  1992-05-25       Impact factor: 5.157

8.  A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients.

Authors:  Jianming Wu; Christine Metz; Xiulong Xu; Riichiro Abe; Andrew W Gibson; Jeffrey C Edberg; Jennifer Cooke; Fenglong Xie; Glinda S Cooper; Robert P Kimberly
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia.

Authors:  Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

10.  Prognostic importance of comorbidity in a hospital-based cancer registry.

Authors:  Jay F Piccirillo; Ryan M Tierney; Irene Costas; Lori Grove; Edward L Spitznagel
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

View more
  7 in total

1.  E2F transcription factor 2 variants as predictive biomarkers for recurrence risk in patients with squamous cell carcinoma of the oropharynx.

Authors:  Yuncheng Li; Erich M Sturgis; Lijun Zhu; Xiaoli Cao; Qingyi Wei; Hua Zhang; Guojun Li
Journal:  Mol Carcinog       Date:  2017-01-02       Impact factor: 4.784

2.  Mouse double minute 4 variants modify susceptibility to risk of recurrence in patients with squamous cell carcinoma of the oropharynx.

Authors:  Zhongming Lu; Erich M Sturgis; Lijun Zhu; Hua Zhang; Ye Tao; Peng Wei; Qingyi Wei; Guojun Li
Journal:  Mol Carcinog       Date:  2017-11-13       Impact factor: 4.784

3.  Modifying effect of mouse double minute-2 promoter variants on risk of recurrence for patients with squamous cell carcinoma of oropharynx.

Authors:  Yang Zhang; Erich M Sturgis; Yuncheng Li; Qingyi Wei; Zhigang Huang; Guojun Li
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

4.  MicroRNA-related polymorphisms in apoptosis pathway genes are predictive of clinical outcome in patients with limited disease small cell lung cancer.

Authors:  Wei Jiang; Nan Bi; Wen-Jue Zhang; Li-Hong Wu; Li-Pin Liu; Yu Men; Jing-Bo Wang; Jun Liang; Zhou-Guang Hui; Zong-Mei Zhou; Lu-Hua Wang
Journal:  Oncotarget       Date:  2016-04-19

5.  The Modifying Effect of a Functional Variant at the miRNA Binding Site in E2F1 Gene on Recurrence of Oropharyngeal Cancer Patients with Definitive Radiotherapy.

Authors:  Hua Zhang; Erich Sturgis; Lijun Zhu; Zhongming Lu; Ye Tao; Hongliang Zheng; Guojun Li
Journal:  Transl Oncol       Date:  2018-03-22       Impact factor: 4.243

6.  Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females.

Authors:  Meng Wang; Zheng Wang; Xi-Jing Wang; Tian-Bo Jin; Zhi-Ming Dai; Hua-Feng Kang; Hai-Tao Guan; Xiao-Bin Ma; Xing-Han Liu; Zhi-Jun Dai
Journal:  Drug Des Devel Ther       Date:  2016-07-25       Impact factor: 4.162

7.  Significance of microRNA-related variants in susceptibility to recurrence of oropharyngeal cancer patients after definitive radiotherapy.

Authors:  Xingming Chen; Erich M Sturgis; Chengyuan Wang; Xiaoli Cao; Yuncheng Li; Qingyi Wei; Guojun Li
Journal:  Oncotarget       Date:  2016-06-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.